David W Kays1, Saleem Islam2, Douglas S Richards3, Shawn D Larson2, Joy M Perkins2, James L Talbert2. 1. Department of Surgery, Division of Pediatric Surgery, University of Florida, Gainesville, FL. Electronic address: david.kays@surgery.ufl.edu. 2. Department of Surgery, Division of Pediatric Surgery, University of Florida, Gainesville, FL. 3. Intermountain Medical Center and the University of Utah, Salt Lake City, UT.
Abstract
BACKGROUND: Congenital diaphragmatic hernia (CDH) is a frequently lethal birth defect and, despite advances, extracorporeal life support (ie, extracorporeal membrane oxygenation [ECMO]) is commonly required for severely affected patients. Published data suggest that CDH survival after 2 weeks on ECMO is poor. Many centers limit duration of ECMO support. STUDY DESIGN: We conducted a single-institution retrospective review of 19 years of CDH patients treated with ECMO, designed to evaluate which factors affect survival and duration of ECMO and define how long patients should be supported. RESULTS: Of two hundred and forty consecutive CDH patients without lethal associated anomalies, 96 were treated with ECMO and 72 (75%) survived. Eighty required a single run of ECMO and 65 survived (81%), 16 required a second ECMO run and 7 survived (44%). Of patients still on ECMO at 2 weeks, 56% survived, at 3 weeks 46% survived, and at 4 weeks, 43% of patients still on ECMO survived to discharge. After 5 weeks of ECMO, survival had dropped to 15%, and after 40 days of ECMO support there were no survivors. Apgar score at 1 minute, Apgar score at 5 minutes, and Congenital Diaphragmatic Hernia Study Group predicted survival all correlated with survival on ECMO, need for second ECMO, and duration of ECMO. Lung-to-head ratio also correlated with duration of ECMO. All survivors were discharged breathing spontaneously with no support other than nasal cannula oxygen if needed. CONCLUSIONS: In patients with severe CDH, improvement in pulmonary function sufficient to wean from ECMO can take 4 weeks or longer, and might require a second ECMO run. Pulmonary outcomes in these CDH patients can still be excellent, and the assignment of arbitrary ECMO treatment durations <4 weeks should be avoided.
BACKGROUND:Congenital diaphragmatic hernia (CDH) is a frequently lethal birth defect and, despite advances, extracorporeal life support (ie, extracorporeal membrane oxygenation [ECMO]) is commonly required for severely affected patients. Published data suggest that CDH survival after 2 weeks on ECMO is poor. Many centers limit duration of ECMO support. STUDY DESIGN: We conducted a single-institution retrospective review of 19 years of CDHpatients treated with ECMO, designed to evaluate which factors affect survival and duration of ECMO and define how long patients should be supported. RESULTS: Of two hundred and forty consecutive CDHpatients without lethal associated anomalies, 96 were treated with ECMO and 72 (75%) survived. Eighty required a single run of ECMO and 65 survived (81%), 16 required a second ECMO run and 7 survived (44%). Of patients still on ECMO at 2 weeks, 56% survived, at 3 weeks 46% survived, and at 4 weeks, 43% of patients still on ECMO survived to discharge. After 5 weeks of ECMO, survival had dropped to 15%, and after 40 days of ECMO support there were no survivors. Apgar score at 1 minute, Apgar score at 5 minutes, and Congenital Diaphragmatic Hernia Study Group predicted survival all correlated with survival on ECMO, need for second ECMO, and duration of ECMO. Lung-to-head ratio also correlated with duration of ECMO. All survivors were discharged breathing spontaneously with no support other than nasal cannula oxygen if needed. CONCLUSIONS: In patients with severe CDH, improvement in pulmonary function sufficient to wean from ECMO can take 4 weeks or longer, and might require a second ECMO run. Pulmonary outcomes in these CDHpatients can still be excellent, and the assignment of arbitrary ECMO treatment durations <4 weeks should be avoided.
Authors: Ravindranath Tiruvoipati; Yana Vinogradova; Gail Faulkner; Andrzej W Sosnowski; Richard K Firmin; Giles J Peek Journal: J Pediatr Surg Date: 2007-08 Impact factor: 2.545
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: G S Lipshutz; C T Albanese; V A Feldstein; R W Jennings; H T Housley; R Beech; J A Farrell; M R Harrison Journal: J Pediatr Surg Date: 1997-11 Impact factor: 2.545
Authors: Cynthia D Downard; Tom Jaksic; Jennifer J Garza; Alexander Dzakovic; Luanne Nemes; Russell W Jennings; Jay M Wilson Journal: J Pediatr Surg Date: 2003-05 Impact factor: 2.545
Authors: David W Kays; Saleem Islam; Joy M Perkins; Shawn D Larson; Janice A Taylor; James L Talbert Journal: J Pediatr Surg Date: 2015-03-14 Impact factor: 2.545
Authors: Sarah B Cairo; Mary Arbuthnot; Laura A Boomer; Michael W Dingeldein; Alexander Feliz; Samir Gadepalli; Chris R Newton; Robert Ricca; Adam M Vogel; David H Rothstein Journal: Pediatr Surg Int Date: 2018-08-21 Impact factor: 1.827
Authors: Patrick T Delaplain; Lishi Zhang; Yanjun Chen; Danh V Nguyen; Matteo Di Nardo; John Patrick Cleary; Peter T Yu; Yigit S Guner Journal: J Pediatr Surg Date: 2017-09-02 Impact factor: 2.545